This study is a retrospective real-world study. In this study, we plan to collect the clinical data of lung metastatic nasopharyngeal carcinoma patients who received PD-1 inhibitors and chemotherapy combined with or without radiotherapy.
age of at least 18 years;
Karnofsky Performance Status (KPS) ≥60;
histologically confirmed nasopharyngeal squamous carcinoma;
metastatic disease after primary standard treatment (patients who had metastatic diseases over six months after treatment);
previous treatment with an immune checkpoint inhibitor;
recurrent disease;
previous systemic chemotherapy for metastatic disease;
symptomatic central nervous system metastases;
Parallel
Control: gemcitabine, cisplatin, tirelizumab
DrugPD-1 inhibitors combined with chemotherapy
Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy
DrugPD-1 inhibitors combined with chemoradiotherapy
Objective response rate
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
